Edition:
India

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

1.58USD
1:30am IST
Change (% chg)

$0.03 (+1.61%)
Prev Close
$1.55
Open
$1.55
Day's High
$1.58
Day's Low
$1.55
Volume
14,810
Avg. Vol
80,031
52-wk High
$22.10
52-wk Low
$1.52

Chart for

About

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop... (more)

Overall

Beta: 2.44
Market Cap(Mil.): $94.42
Shares Outstanding(Mil.): 35.63
Dividend: --
Yield (%): --

Financials

BRIEF-Versartis Q4 Earnings Per Share $0.87

* VERSARTIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

02 Mar 2018

BRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc

* ADVENT LIFE SCIENCES LLP REPORTS A 4.5 PERCENT PASSIVE STAKE IN VERSARTIS, INC. AS OF DEC 31, 2017 - SEC FILING Source text - http://bit.ly/2EuDXO8 Further company coverage:

08 Feb 2018

BRIEF-Versartis Inc Says Board Appointed Jay Shepard, CEO, To Position Of Principal Financial Officer

* VERSARTIS INC SAYS ‍ON NOV 28, 2017, BOARD APPOINTED JAY SHEPARD, CEO, TO POSITION OF PRINCIPAL FINANCIAL OFFICER, EFFECTIVE DEC 1, 2017 - SEC FILING​ Source text (http://bit.ly/2A3BTve) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

05 Dec 2017

BRIEF-Versartis hires Cowen to assist in evaluating potential strategic transactions

* Versartis hires Cowen to assist in evaluating potential strategic transactions

27 Oct 2017

BRIEF-Versartis reports Q3 loss $1.40/shr

* Versartis reports third quarter 2017 financial results and provides corporate update

27 Oct 2017

Earnings vs. Estimates